TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34933930
Drug: Three potentially
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three potentially neuroprotective drugs
Study: 32106869
Drug: Oral (PO)
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral (PO) administration of diclofenac
Study: 32106869
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) administration of diclofenac
Study: 35689284
Drug: Knee sleeve
Normalized name: Knee Sleeve Large
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knee sleeve worn for 6 weeks at least 1 hour daily (Sleeve Group, n=9)
Study: 35129469
Drug: N-acetyl-cysteine (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-cysteine (NAC) 1200 mg twice-daily for up to 5 days postoperatively
Study: 32880953
Drug: Dialectical Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behavior Therapy Skills Training Group (DBT‐ST), n=16
Study: 32880953
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TaU), n=15
Study: 32212518
Drug: Luspatercept (1.00
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luspatercept (1.00 to 1.25 mg/kg)
Study: 35011579
Drug: Sunitinib or
Normalized name: sunitinib Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib or Pazopanib (anti-angiogenic drugs)
Study: 35839108
Drug: Phenylephrine combined
Normalized name: phenylephrine, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine combined with Goal-Directed Fluid Therapy (GDFT)
Study: 35839108
Drug: Goal-Directed Fluid
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-Directed Fluid Therapy (GDFT) alone
Study: 32885482
Drug: Overdentures retained
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Overdentures retained by 1 implant (Group I)
Study: 32885482
Drug: Overdentures retained
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Overdentures retained by 2 implants (Group II)
Study: 32885482
Drug: Fixed hybrid
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed hybrid prosthesis on 4 implants (Group III)
Study: 35324465
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg daily with bevacizumab 10 mg/kg i.v. every 2 weeks
Study: 33377368
Drug: Chicken-based oral
Normalized name: Chicken
DrugBank: Chicken (DB10519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chicken-based oral nutritional supplement (ONS)
Study: 33377368
Drug: Placebo (similarly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (similarly flavored oral fluid)
Study: 33092527
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (20 mL)
Study: 34956561
Drug: Anlotinib capsules
Normalized name: nilotinib Oral Capsule
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib capsules combined with PD-1 inhibitor (camrelizumab)
Study: 34956561
Drug: Single treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment group (STG) with anlotinib only
Study: 32597302
Drug: PGx-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGx-guided treatment
Study: 35701155
Drug: T2T tapering
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: T2T tapering strategy (N=81)
Study: 35701155
Drug: T2T no-tapering
Normalized name: NO
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: T2T no-tapering strategy (N=41)
Study: 36073613
Drug: Hemostatic therapy
Normalized name: collagen hemostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemostatic therapy guided by viscoelastic hemostatic assays (VHA)
Study: 36073613
Drug: Hemostatic therapy
Normalized name: collagen hemostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemostatic therapy guided by conventional coagulation tests (CCT)
Study: 34520230
Drug: Hepatectomy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hepatectomy followed by 12 courses of adjuvant mFOLFOX6 chemotherapy
Study: 33159530
Drug: Neuromuscular blocking
Normalized name: Neuromuscular blocking agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular blocking agents (NMBAs)
Study: 32768967
Drug: Melatonin (MEL)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin (MEL) 25 mg administered at noon and 30 min before bedtime for three months
Study: 32768967
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at noon and 30 min before bedtime for three months
Study: 35641569
Drug: Digital support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital support system with daily weight measurements
Study: 34397733
Drug: MCT oil
Normalized name: Organic MCT Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT oil massage (10 mL/kg/day of MCT oil divided into three applications)
Study: 32993528
Drug: Ultrasound-guided thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided thoracic paravertebral block (PVB) with 20 mL 0.25% bupivacaine as a single administration.
Study: 36127337
Drug: Single-dose oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose oxytocin (24 international units)
Study: 36127337
Drug: Multiple-dose oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-dose oxytocin (4 weeks of once-daily nasal spray)
Study: 35218301
Drug: Acitretin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin 0.5 mg/kg/day (group B)
Study: 32590942
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg rifabutin every other day (E.O.D) with lopinavir/ritonavir
Study: 32590942
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg rifabutin every other day (E.O.D) with lopinavir/ritonavir
Study: 33681731
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 400 mg BID x1day, followed by 200 mg BID x9days
Study: 33681731
Drug: Hydroxychloroquine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine with Azithromycin (HCQ/AZ) 500 mg, then 250 mg daily x4days
Study: 35722886
Drug: Docosahexaenoic acid
Normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docosahexaenoic acid (DHA) 2 g/day
Study: 34454582
Drug: Fascial manipulation
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fascial manipulation (FM) and sequential yoga poses (SYP)
Study: 35263150
Drug: Short-term radiotherapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term radiotherapy (25 Gy in five fractions over 1 week) followed by four cycles of chemotherapy (total neoadjuvant therapy [TNT])
Study: 34259635
Drug: Counselor-initiated treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counselor-initiated treatment
Study: 34259635
Drug: Self-paced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-paced treatment
Study: 34900185
Drug: Standard stroke
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard stroke treatment
Study: 35561092
Drug: Real-time remote
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time remote access to child's glucose and insulin data by healthcare professionals
Study: 33044768
Drug: Grape seed
Normalized name: grape seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape seed extract (GSE) 300 mg/day
Study: 32571720
Drug: FMP2.1/AS02A malaria
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMP2.1/AS02A malaria vaccine
Study: 36257912
Drug: Latanoprost eye
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost eye drops and minoxidil 5% solution
Study: 36257912
Drug: Betamethasone and
Normalized name: betamethasone and mydriatics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone and minoxidil 5% solution
Study: 36257912
Drug: Betamethasone solution
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone solution and latanoprost eye drops
Study: 36257912
Drug: Betamethasone solution
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone solution
Study: 32380132
Drug: Two‐step impression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two‐step impression (custom tray, border molding with compound, and polyether)
Study: 36000427
Drug: Paroxetine-mediated G-protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine-mediated G-protein receptor kinase 2 inhibition
Study: 34702654
Drug: Mexiletine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (200 mg/day up-titrated to 600 mg/day over 18 days)
Study: 35854347
Drug: 6-week hybrid
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6-week hybrid mindfulness-based intervention (MBI) consisting of 6 weekly 90-min group-based sessions delivered through face-to-face and online approach.
Study: 36063140
Drug: Non-receipt of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-receipt of emergency assistance (treatment group who did not receive assistance)
Study: 32061968
Drug: Two-hour educational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-hour educational workshop about a patient-centered approach to opioid therapy
Study: 35994868
Drug: Educational program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational program attended once weekly for 4 weeks
Study: 33801705
Drug: Nefopam 240
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam 240 mg (Group N240)
Study: 33801705
Drug: Nefopam 120
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam 120 mg with fentanyl 600 μg (Group NF)
Study: 35939810
Drug: Intravenous ensovibep,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ensovibep, 600 mg
Study: 34495336
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU of oral vitamin D3 supplementation daily
Study: 34495336
Drug: 1200 IU
Normalized name: Vitamin E 1200 IU Oral Capsule, Liquid Filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 IU of oral vitamin D3 supplementation daily
Study: 34376917
Drug: Test food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test food containing anthocyanin, astaxanthin, and lutein, taken as 2 capsules once daily for 6 weeks
Study: 34376917
Drug: Placebo, taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, taken as 2 capsules once daily for 6 weeks
Study: 36003050
Drug: Lacticaseibacillus rhamnosus
Normalized name: Lacticaseibacillus rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacticaseibacillus rhamnosus GG (LGG) 1 x 10^10 CFU/daily for 12 weeks
Study: 38797183
Drug: No vaccine
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: No vaccine
Study: 35748547
Drug: Echium amoenum-Melissa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echium amoenum-Melissa officinalis syrup and fluvoxamine
Study: 35748547
Drug: Placebo syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo syrup and fluvoxamine
Study: 33938966
Drug: Intraoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative radiotherapy (IORT) with a single dose of 20 Gy
Study: 36229604
Drug: Self-regulation teaching
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-regulation teaching unit based on mental contrasting with implementation intentions; details on dosage and duration not specified.
Study: 33201025
Drug: 2RDA (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2RDA (1.6 g/kg body weight)
Study: 33201025
Drug: RDA (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: RDA (0.8 g/kg body weight)
Study: 33141790
Drug: CSM-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSM-based intervention consisting of five weekly group-based education sessions
Study: 33141790
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving five weekly educational booklets
Study: 38950993
Drug: Graded Exposure
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded Exposure Therapy (GET)
Study: 32411324
Drug: L-Glutamine (Gln)
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Glutamine (Gln) supplementation
Study: 32411324
Drug: L-Glutamine (Gln)
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Glutamine (Gln) supplementation in CET group
Study: 32411324
Drug: L-Glutamine (Gln)
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Glutamine (Gln) supplementation in NP group
Study: 34000958
Drug: Faecal microbiota
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faecal microbiota transplantation (FMT) capsules for 12 days
Study: 34000958
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules for 12 days
Study: 32919779
Drug: Aspirin use
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin use (≥once/week)
Study: 32919779
Drug: Daily use
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily use of aspirin
Study: 32919779
Drug: Daily use
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily use of low-dose aspirin
Study: 32175586
Drug: Acetazolamide (AZ)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (AZ) 250 mg twice daily for 3.5 days
Study: 32720823
Drug: Colchicine 1
Normalized name: colchicine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 1 mg orally 12 to 24 hours before surgery followed by 0.5 mg daily until discharge
Study: 33479775
Drug: Adjunctive 1000
Normalized name: ANESTHETIC ADJUNCTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive 1000 mg aspirin
Study: 32598248
Drug: Drug-polymer interaction
Normalized name: Methacrylic Acid Copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-polymer interaction study
Study: 34262711
Drug: Food ration
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food ration bars enriched with arginine (2 g/day), ß‐alanine (2 g/day), and Nigella sativa (2 g/day)
Study: 36191080
Drug: GSK3732394 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3732394 (10 mg starting dose, single ascending doses)
Study: 36191080
Drug: GSK3732394 (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3732394 (maximum dose 80 mg)
Study: 34389168
Drug: Goal-directed fluid
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed fluid therapy (GDT group)
Study: 34389168
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous fluid therapy (STD group)
Study: 33926423
Drug: Double combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double combination of oral OADs (sulfonylurea and thiazolidinediones)
Study: 33926423
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination of oral OADs (metformin, sulfonylurea, and thiazolidinediones)
Study: 32661909
Drug: Elacestrant 200
Normalized name: Elacestrant
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elacestrant 200 mg daily
Study: 32661909
Drug: Elacestrant 500
Normalized name: Elacestrant
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elacestrant 500 mg daily
Study: 32661909
Drug: Elacestrant (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elacestrant (up to 1000 mg daily)
Study: 32661909
Drug: Elacestrant (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elacestrant (500 mg dose)
Study: 32661909
Drug: Elacestrant (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elacestrant (200 mg dose)
Study: 32759285
Drug: Freeze-all group
Normalized name: Freez Eez
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze-all group (elective freezing of all embryos) with gonadotropin releasing hormone agonist triggering and single frozen-thawed blastocyst transfer in a subsequent modified natural cycle.
Study: 35598008
Drug: Metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin hydrochloride sustained-release tablets (0.5 g/day for the first 2 weeks, 1 g/day for the second 2 weeks, and 2 g/day for the remaining period if tolerated)
Study: 35598008
Drug: Metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin hydrochloride sustained-release tablets
Study: 35291399
Drug: Bupivacaine 2.5
Normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2.5 mg/mL 20 mL plus dexmedetomidine 100 µg
Study: 35291399
Drug: Bupivacaine 20
Normalized name: BUPIVACAINE 200MG/MELOXICAM 6MG/VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 20 mL alone
Study: 36329553
Drug: Genistein 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genistein 120 mg daily for 12 months
Study: 34679188
Drug: Libre del
Approvals — FDA: no, EMA: no, PMDA: no
Description: Libre del Cigarrillo (LDC) - 11 booklets and 9 pamphlets mailed monthly over 18 months
Study: 35191716
Drug: Cognitive-behavioral couple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral couple therapy (CBCT) for 12 weeks
Study: 35191716
Drug: Lidocaine treatment
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine treatment for 12 weeks
Study: 35731251
Drug: Solifenacin added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin added to intradetrusor injections of BoNT A
Study: 35731251
Drug: Intradetrusor injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradetrusor injections of BoNT A
Study: 34368888
Drug: Skills treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skills treatment (TX) workshops
Study: 34461961
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 ?g/day) for 16 weeks, continuing to 24 weeks if fracture remains unhealed
Study: 33030269
Drug: 900 mL
Normalized name: OXYGEN 900 mL in 1 L RESPIRATORY (INHALATION) GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mL blood donation
Study: 33030269
Drug: 450 mL
Normalized name: ALCOHOL 270 mL in 450 mL EXTRACORPOREAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mL blood donation
Study: 33030269
Drug: Sham donation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham donation of 900 mL
Study: 33030269
Drug: Sham donation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham donation of 450 mL
Study: 33030269
Drug: Plasma proANP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma proANP after 900 mL blood donation
Study: 33030269
Drug: Plasma proANP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma proANP after 450 mL blood donation
Study: 33030269
Drug: Plasma proANP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma proANP after sham donation of 900 mL
Study: 33030269
Drug: Plasma proANP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma proANP after sham donation of 450 mL
Study: 33030269
Drug: Stroke volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stroke volume after 900 mL blood donation
Study: 34032799
Drug: Interactive Video
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive Video Gaming (IVG) group, 12-week intervention, 2 x 1 hour sessions weekly
Study: 34032799
Drug: Conventional Multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Multimodal (CM) group, 12-week intervention, 2 x 1 hour sessions weekly
Study: 36346729
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (5 mg infusion, once at the start of the study)
Study: 32282432
Drug: Subcutaneous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous nitroglycerin (5 μg/kg in 0.5 ml)
Study: 35019221
Drug: linaclotide (290
Approvals — FDA: no, EMA: no, PMDA: no
Description: linaclotide (290 μg/d)
Study: 33239245
Drug: Single low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single low-dose ketamine infusion of 0.5 mg/kg
Study: 34959813
Drug: Breakfast Consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfast Consumption (BC) - daily standardized breakfast consumption (energy content: 25% of resting metabolic rate) before 09:00
Study: 33200905
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg/die plus tamsulosin 0.4 mg/die combination therapy for 12 weeks
Study: 33334838
Drug: Dexamethasone on
Normalized name: Dexamethasone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone on day 1 combined with NK1-RA, Palonosetron, and Olanzapine (5 mg)
Study: 35931041
Drug: Ketamine infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusions (0.5 mg/kg over 40 minutes)
Study: 34579067
Drug: Carotenoid supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotenoid supplementation (14 mg zeaxanthin/7 mg lutein)
Study: 32471891
Drug: CHIPS administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHIPS administration